Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/67908
DC FieldValueLanguage
dc.contributor.authorChen, D.Y.en_US
dc.contributor.authorShen, G.H.en_US
dc.contributor.authorHsieh, T.Y.en_US
dc.contributor.authorHsieh, C.W.en_US
dc.contributor.authorLan, J.L.en_US
dc.date2008zh_TW
dc.date.accessioned2014-06-11T05:55:55Z-
dc.date.available2014-06-11T05:55:55Z-
dc.identifier.issn0004-3591zh_TW
dc.identifier.urihttp://hdl.handle.net/11455/67908-
dc.description.abstractObjective. To investigate QuantiFERON-tuberculosis Gold (QFT-G) assay and tuberculin skin test (TST) for latent tuberculosis (TB) infection (LTBI) in patients with rheumatoid arthritis (RA) treated with adalimumab. Methods. We prospectively followed up 43 RA patients who received adalimumab therapy and underwent serial TSTs and QFT-G assays. TST was performed using Mantoux method and QFT-G assay was examined by measuring interferon-gamma levels in whole blood samples that were incubated with early secretary antigenic target-6 and culture filtrate protein 10. Results. Before starting adalimumab therapy, 8 RA patients (18.6%) had positive and 35 (81.4%) had negative TST results. All 8 RA patients with positive TST results were diagnosed as LTBI and received isoniazid prophylaxis (INHP) 1 month before starting adalimumab therapy. None of these 8 RA patients developed active TB 2 years after completing INHP. A high rate (10 [37.0%] patients) of TST conversion was observed among 27 patients who had completed 12-month adalimumab therapy. Of these 10 patients with TST conversion, 2 patients had positive QFT-G results and 1 developed active TB disease. Among 17 RA patients who did not have TST conversion after 12-month adalimumab therapy, 1 patient who had a positive QFT-G result developed active TB disease. Of all 43 RA patients who received adalimumab therapy, 4 (9.3%) developed active TB after starting adalimumab therapy. Conclusion. The application of TST for detecting LTBI is limited in RA patients by the frequent presence of anergy. Combined QFT-G assay and TST can aid in detecting LTBI in RA patients receiving adalimumab therapy.en_US
dc.language.isoen_USzh_TW
dc.relationArthritis & Rheumatism-Arthritis Care & Researchen_US
dc.relation.ispartofseriesArthritis & Rheumatism-Arthritis Care & Research, Volume 59, Issue 6, Page(s) 800-806.en_US
dc.relation.urihttp://dx.doi.org/10.1002/art.23705en_US
dc.subjectantitumor necrosis factoren_US
dc.subjecthealth-care workersen_US
dc.subjectcell-based assayen_US
dc.subjectmycobacterium-tuberculosisen_US
dc.subjectnontuberculous mycobacteriaen_US
dc.subjectantituberculosis therapyen_US
dc.subjectpulmonary tuberculosisen_US
dc.subjectactive tuberculosisen_US
dc.subjectfactor antagonistsen_US
dc.subjectunited-statesen_US
dc.titleEffectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapyen_US
dc.typeJournal Articlezh_TW
dc.identifier.doi10.1002/art.23705zh_TW
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en_US-
item.fulltextno fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:期刊論文
Show simple item record
 

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.